135 related articles for article (PubMed ID: 10088933)
1. Changes in pulmonary function in preterm infants recovering from RDS following early treatment with ambroxol: results of a randomized trial.
Schmalisch G; Wauer RR; Böhme B
Pediatr Pulmonol; 1999 Feb; 27(2):104-12. PubMed ID: 10088933
[TBL] [Abstract][Full Text] [Related]
2. Effect of early ambroxol treatment on lung functions in mechanically ventilated preterm newborns who subsequently developed a bronchopulmonary dysplasia (BPD).
Schmalisch G; Wauer RR; Böhme B
Respir Med; 2000 Apr; 94(4):378-84. PubMed ID: 10845438
[TBL] [Abstract][Full Text] [Related]
3. Antenatal ambroxol usage in the prevention of infant respiratory distress syndrome. Beneficial and adverse effects.
Kimya Y; Küçükkömürcü S; Ozan H; Uncu G
Clin Exp Obstet Gynecol; 1995; 22(3):204-11. PubMed ID: 7554258
[TBL] [Abstract][Full Text] [Related]
4. Prevention of respiratory distress syndrome in preterm infants by antenatal ambroxol: a meta-analysis of randomized controlled trials.
Zhang ZQ; Wu QQ; Huang XM; Lu H
Am J Perinatol; 2013 Aug; 30(7):529-36. PubMed ID: 23229957
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of ambroxol given prenatally and postnatally on gas exchange in the newborn with respiratory distress syndrome].
Sackey S; Gadzinowski J; Szymankiewicz M; Breborowicz GH; Rudnicki J; Patalan J; Rózewicki K
Ginekol Pol; 1995 Jul; 66(7):409-12. PubMed ID: 8655006
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of intravenous or atomizing ambroxol for prevention of respiratory distress syndrome in preterm infants].
Hu Q; Lian JM; Li JQ
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Aug; 8(4):301-3. PubMed ID: 16923362
[TBL] [Abstract][Full Text] [Related]
7. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome.
Wauer RR; Schmalisch G; Böhme B; Arand J; Lehmann D
Eur J Pediatr; 1992 May; 151(5):357-63. PubMed ID: 1396891
[TBL] [Abstract][Full Text] [Related]
8. A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS).
Lazzarin A; Luerti M; Capsoni F; Galli M; Uberti-Foppa C; Zavattini G; Corbella E
Int J Tissue React; 1986; 8(2):157-65. PubMed ID: 3700005
[TBL] [Abstract][Full Text] [Related]
9. [Antenatal ambroxol administration for prevention of respiratopry distress syndrome in preterm infants: preliminary report].
Marinov B; Jekova N; Andreeva A; Hitrova S
Akush Ginekol (Sofiia); 2011; 50(4):17-22. PubMed ID: 22479892
[TBL] [Abstract][Full Text] [Related]
10. Antenatal ambroxol treatment does not prevent the respiratory distress syndrome in premature infants.
Dani C; Grella PV; Lazzarin L; Rubaltelli FF
Eur J Pediatr; 1997 May; 156(5):392-3. PubMed ID: 9177984
[TBL] [Abstract][Full Text] [Related]
11. [Surfactant and ambroxol in the therapy of idiopathic respiratory syndrome in newborn infants].
Carrera G; Liberatore A; Riboni G; Clementi M
Minerva Pediatr; 1991 Nov; 43(11):723-30. PubMed ID: 1791799
[TBL] [Abstract][Full Text] [Related]
12. Polymorphonuclear leucocytes functions from premature infants after prevention of respiratory distress syndrome with betamethasone and ambroxol.
Lazzarin A; Luerti M; Uberti-Foppa C; Zavattini G; Rossi A; Tornaghi R
Biol Res Pregnancy Perinatol; 1984; 5(3):130-4. PubMed ID: 6478010
[TBL] [Abstract][Full Text] [Related]
13. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS.
Stevens TP; Blennow M; Soll RF
Cochrane Database Syst Rev; 2002; (2):CD003063. PubMed ID: 12076469
[TBL] [Abstract][Full Text] [Related]
14. [The effectiveness of prenatal steroid and ambroxol therapy for the prevention of respiratory distress syndrome in newborns of diabetic mothers].
Bomba-Opoń DA; Wiczyńska-Zajac A; Domańska-Janczewska E; Kociszewska-Najman B; Marianowski L
Ginekol Pol; 2000 Aug; 71(8):887-92. PubMed ID: 11082943
[TBL] [Abstract][Full Text] [Related]
15. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.
Stevens TP; Blennow M; Soll RF
Cochrane Database Syst Rev; 2004; (3):CD003063. PubMed ID: 15266470
[TBL] [Abstract][Full Text] [Related]
16. Ambroxol in the treatment of idiopathic respiratory distress syndrome. An interim report on a controlled double-blind multicenter study versus placebo.
Marini A; Franzetti M; Gios G; Flauto U; Arosio A; Maccabruni M; Rondini G; Chirico G; Giancola A; Console V
Respiration; 1987; 51 Suppl 1():60-7. PubMed ID: 3299568
[TBL] [Abstract][Full Text] [Related]
17. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant.
Abbasi S; Bhutani VK; Gerdes JS
J Pediatr; 1993 Mar; 122(3):446-52. PubMed ID: 8441104
[TBL] [Abstract][Full Text] [Related]
18. Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome.
Laoag-Fernandez JB; Fernandez AM; Maruo T
J Obstet Gynaecol Res; 2000 Aug; 26(4):307-12. PubMed ID: 11049243
[TBL] [Abstract][Full Text] [Related]
19. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
Fujii A; Allen R; Doros G; O'Brien S
J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
[TBL] [Abstract][Full Text] [Related]
20. Predictors of successful extubation of preterm low-birth-weight infants with respiratory distress syndrome.
Szymankiewicz M; Vidyasagar D; Gadzinowski J
Pediatr Crit Care Med; 2005 Jan; 6(1):44-9. PubMed ID: 15636658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
